Get the Stockscreener App
8.69
6.96%
-0.65
Vir Biotechnology Inc stock is traded at $8.69, with a volume of 2.15M.
It is down -6.96% in the last 24 hours and down -12.66% over the past month.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
See More
Previous Close:
$9.34
Open:
$9
24h Volume:
2.15M
Relative Volume:
1.17
Market Cap:
$1.47B
Revenue:
$68.56M
Net Income/Loss:
$-437.99M
P/E Ratio:
-2.7466
EPS:
-3.1639
Net Cash Flow:
$-396.61M
1W Performance:
-7.85%
1M Performance:
-12.66%
6M Performance:
+14.95%
1Y Performance:
+50.87%
1-Day Range:
$8.62
$9.15
1-Week Range:
$8.62
$9.59
52-Week Range:
$4.155
$11.66
Vir Biotechnology Inc Stock (VIR) Company Profile
Name
Vir Biotechnology Inc
Sector
Industry
Phone
415-906-4324
Address
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
8.69 | 1.47B | 68.56M | -437.99M | -396.61M | -3.1639 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-03-25 | Initiated | Evercore ISI | Outperform |
| Aug-27-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-29-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-08-23 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Feb-21-23 | Upgrade | Goldman | Neutral → Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-14-22 | Initiated | SVB Leerink | Outperform |
| Sep-09-22 | Initiated | Morgan Stanley | Underweight |
| Mar-03-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Dec-21-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Oct-25-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Jan-27-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-05-20 | Initiated | BofA Securities | Buy |
| Sep-14-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-11-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-20-20 | Initiated | Needham | Buy |
| Mar-19-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-13-20 | Downgrade | Goldman | Buy → Neutral |
| Feb-27-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Feb-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-14-19 | Initiated | Robert W. Baird | Neutral |
| Nov-05-19 | Initiated | Barclays | Overweight |
| Nov-05-19 | Initiated | Cowen | Outperform |
| Nov-05-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | JP Morgan | Overweight |
View All
Vir Biotechnology Inc Stock (VIR) Latest News
Vir Biotechnology Inc (VIR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Vir Biotechnology Inc (VIR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
VIR|Vir Biotechnology Inc|Price:8.675|Chg%:-0.665 - TradingKey
Vir Biotechnology: Sabatini Has Served as Senior Vice Pres and Chief Acctg Officer Since Feb 2023 >VIR - Moomoo
Why is Vir Biotechnology stock sliding today? By Investing.com - Investing.com Canada
Vir Biotechnology (VIR) Announces New Interim Financial Leadersh - GuruFocus
Vir Biotechnology (NASDAQ:VIR) Shares Gap DownWhat's Next? - MarketBeat
Vir Biotechnology (VIR) Appoints Interim Financial Officer Amid Leadership Changes - GuruFocus
Vir Biotechnology stock falls as CFO O’Byrne departs - Investing.com
Vir Biotechnology Appoints Brent Sabatini as Interim Principal Financial Officer - Moomoo
Vir Biotechnology Announces Chief Financial Officer Transition - BioSpace
Vir Biotechnology, Inc. Announces Resignation of Jason O'Byrne as Executive Vice President, Effective August 3, 2026 - marketscreener.com
Vir Biotechnology Appoints Brent Sabatini as Interim CFO Following Jason O'Byrne's Resignation - Kalkine Media
Vir Biotechnology names interim finance chief - Investing.com
Vir Biotechnology (VIR) TD Cowen 46th Annual Health Care Conference Summary - Quartr
Vir Biotechnology names interim finance chief By Investing.com - Investing.com Canada
VIR Q2'26 Earnings: revenue estimate is 135.88M USD - TradingView
Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results - BioSpace
Vir Biotechnology to host conference call for Q2 2026 results - scanx.trade
Vir Biotechnology, Inc. (VIR) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Vir Biotechnology, Inc. (VIR) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership - Stocktwits
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Vir Biotechnology (VIR) Bank of America Global Healthcare Conference 2026 Summary - Quartr
VIR stock reacts to latest clinical updates and cash position - Ad-hoc-news.de
Why Did Vir Biotechnology Stock Surge 60% After-Hours Today? - Stocktwits
Vir Biotechnology nears key trial results in he... - Pluang
Vir Biotechnology: Multiple Catalysts In Hepatitis And Oncology Ahead (NASDAQ:VIR) - Seeking Alpha
Vir Biotechnology, Inc. (VIR) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Hillsdale Investment Management Inc. Invests $1.44 Million in Vir Biotechnology, Inc. $VIR - MarketBeat
Discipline and Rules-Based Execution in VIR Response - Stock Traders Daily
Vir Biotechnology, Inc. $VIR Shares Bought by Candriam S.C.A. - MarketBeat
Y Intercept Hong Kong Ltd Takes Position in Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology (VIR) BofA Securities 2025 Healthcare Conference Summary - Quartr
Will Vir Biotechnology (NASDAQ:VIR) Spend Its Cash Wisely? - Moomoo
A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $16 to $30 - Moomoo
Vir Biotechnology, Inc. $VIR Stock Holdings Increased by Pictet Asset Management Holding SA - MarketBeat
VIRVir Biotechnology Inc Latest SEC Filings - Finviz
OP Asset Management Ltd Takes Position in Vir Biotechnology, Inc. $VIR - MarketBeat
Form 144 Vir Biotechnology For: 29 June By Investing.com - Investing.com South Africa
Why Is Vir Biotechnology (NASDAQ:VIR) Turning Heads In Small-Caps? - Kalkine Media
[144] Vir Biotechnology, Inc. SEC Filing - Stock Titan
Enterprise value to EBIT forward of Vir Biotechnology, Inc. – NASDAQ:VIR - TradingView
Price to sales forward of Vir Biotechnology, Inc. – NASDAQ:VIR - TradingView
Price to book forward of Vir Biotechnology, Inc. – NASDAQ:VIR - TradingView
Enterprise value to revenue forward of Vir Biotechnology, Inc. – NASDAQ:VIR - TradingView
Price to earnings forward of Vir Biotechnology, Inc. – NASDAQ:VIR - TradingView
Vir Biotechnology, Inc. Actuals & Estimates (NASDAQ:VIR) - TradingView
VIR Forecast — Price Target — Prediction for 2027 - TradingView
H.C. Wainwright Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Vir Biotechnology Inc (VIR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Vir Biotechnology Inc Stock (VIR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vir Biotechnology Inc Stock (VIR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Napolitano Janet | Director |
Jun 01 '26 |
Sale |
9.45 |
3,200 |
30,240 |
21,216 |
| Sabatini Brent | SVP, Chief Accounting Officer |
Jun 01 '26 |
Sale |
9.45 |
379 |
3,582 |
61,902 |
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):